- Home
- LPTX vs NXTC Comparison
LPTX vs NXTC Comparison
Compare LPTX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- NXTC
- Stock Information
- Founded
- LPTX 2011
- NXTC 2015
- Country
- LPTX United States
- NXTC United States
- Employees
- LPTX N/A
- NXTC N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LPTX Health Care
- NXTC Health Care
- Exchange
- LPTX Nasdaq
- NXTC Nasdaq
- Market Cap
- LPTX 11.1M
- NXTC 13.0M
- IPO Year
- LPTX N/A
- NXTC 2019
- Fundamental
- Price
- LPTX $0.75
- NXTC N/A
- Analyst Decision
- LPTX Hold
- NXTC Strong Buy
- Analyst Count
- LPTX 1
- NXTC 2
- Target Price
- LPTX N/A
- NXTC $25.50
- AVG Volume (30 Days)
- LPTX 7.6M
- NXTC 10.5K
- Earning Date
- LPTX 11-12-2025
- NXTC 11-06-2025
- Dividend Yield
- LPTX N/A
- NXTC N/A
- EPS Growth
- LPTX N/A
- NXTC N/A
- EPS
- LPTX N/A
- NXTC N/A
- Revenue
- LPTX N/A
- NXTC N/A
- Revenue This Year
- LPTX N/A
- NXTC N/A
- Revenue Next Year
- LPTX N/A
- NXTC N/A
- P/E Ratio
- LPTX N/A
- NXTC N/A
- Revenue Growth
- LPTX N/A
- NXTC N/A
- 52 Week Low
- LPTX $0.22
- NXTC $2.69
- 52 Week High
- LPTX $4.79
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- LPTX 63.63
- NXTC N/A
- Support Level
- LPTX $0.46
- NXTC N/A
- Resistance Level
- LPTX $0.98
- NXTC N/A
- Average True Range (ATR)
- LPTX 0.11
- NXTC 0.00
- MACD
- LPTX 0.03
- NXTC 0.00
- Stochastic Oscillator
- LPTX 51.58
- NXTC 0.00
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.